- Global Pharma News & Resources

Asthma Spacers: Spacer devices for inhaled therapy(Global Research) announces the publication of its most recently generated research report titled, “Global Asthma Spacers Market by Product Type (Aerochamber, Optichamber, Volumatic, Inspirease), by distribution channel (Retail Pharmacy, Hospital Pharmacy, and E-commerce) and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). Global Forecast to 2028.”, which offers a holistic view of the asthma spacers market through systematic segmentation that covers every aspect of the target market. The first five-year cumulative revenue (2019–2023) is projected to be more than US$ 8 Bn which is expected to increase relatively over the latter part of the five-year forecast period.

Browse the full “Asthma Spacers Market By Product Type (Aerochamber, Optichamber, Volumatic, Inspirease), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, And E-Commerce), And Region – Global Forecast To 2028”


Asthma is a chronic respiratory condition that affects people of all ages. Asthma spacers are designed to counter problems associated with medication errors related to dosage formulation issues and help in achieving maximum safety and drug efficacy by accurate drug delivery in the pulmonary system of patients suffering from a respiratory disease.

Prominent players of Asthma Spacers Market including:

Koninklijke Philips N.V., Merck & Co., Inc., PARI GmbH, AstraZeneca Plc, GlaxoSmithKline Plc, Cipla Inc., Trudell Medical Group Ltd., Medical Developments International Limited, Lupin Limited, Sanofi S.A. (Fisons plc)

Editor Details

Last Updated: 22-Jan-2021